Why Sarepta’s latest trial data may presage another FDA controversy
One year after scoring one of the most controversial FDA approvals in recent history, Cambridge-based Sarepta Therapeutics may again find itself at the center of a debate over the agency ’s standards with a new experimental drug.
Sarepta (Nasdaq: SRPT) on Wednesday unveiled data from a small, early-stage trial of one of its potential treatments for Duchenne muscular dystrophy, a genetic disorder in which the absence of a protein called dystrophin causes progressive muscle weaknes s. According to…
Source: bizjournals.com Health Care:Biotechnology headlines - Category: Biotechnology Authors: Max Stendahl Source Type: news
More News: Biotechnology | Genetics | Health Management | Muscular Dystrophy | Reflex Sympathetic Dystrophy